NCT07866235Completed
Comparing The Effect Of Empagliflozin With Dapagliflozin In Reducing Proteinuria In Diabetic Patients With Chronic Kidney Disease With eGFR More Than 45ml/Min/1.73m²
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
This study was designed to compare empagliflozin and dapagliflozin in reducing protein leakage into the urine in adults with type 2 diabetes and chronic kidney disease. It examined whether the two medicines differed in their effects on urine protein levels. Blood sugar control, kidney function, treatment costs, and side effects were also selected for comparison. The study was planned as a randomized controlled trial at the Nephrology Department of Lahore General Hospital, Lahore, Pakistan. The planned sample comprised 116 men and women aged 20-70 years who had increased urine albumin levels and an estimated glomerular filtration rate, a measure of kidney filtration, above 45 mL/min/1.73 m². Participants were to be assigned by a lottery method to two equal groups of 58 patients. One group was to receive dapagliflozin 5 mg once daily, and the other empagliflozin 10 mg once daily. Assessments were scheduled before treatment and after two and four months. The main assessment was the change in the urine albumin-to-creatinine ratio, which measured the amount of albumin, a blood protein, leaking into the urine. Other assessments included blood tests for kidney function and average blood sugar levels. Treatment costs and side effects, including low blood sugar, urinary tract infections, oral thrush, dehydration, allergic reactions, body pains, and kidney failure, were also included in the follow-up plan. The study aimed to compare the benefits, safety, and costs of these treatments in the selected patients.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 116 (actual)
- First submitted
- 4 Oct 2026
- Start date
- 11 Oct 2023
- Primary completion date
- 10 Apr 2024
- Lead sponsor
- Lahore General Hospital
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT07866235
What you commit to
- Study type: Interventional
- Participants enrolled: 116
- From 11 Oct 2023 to the primary completion date, 10 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Type 1 diabetes mellitus.
- Hypersensitivity to the study medications.
Age
- Age below 20 years or above 70 years.
Other
- Pregnancy.
Who the study is looking for
- Age 20-70 years.
- Male or female patients.
- Type 2 diabetes mellitus with chronic kidney disease.
- Body mass index ≤45.0 kg/m².
- Urinary albumin-to-creatinine ratio \>30 mg/g.
- Estimated glomerular filtration rate \>45 mL/min/1.73 m².
- Stable dose of an oral antidiabetic medication for at least 4 weeks, or insulin, either alone or with an oral antidiabetic medication, for 8 weeks.
- Stable dose of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker for at least 4 weeks.
Age in the registry: 20 months to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lahore General Hospital, Lahore Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.